Short Summary
The plaintiffs, owners of the trademark 'Septran' and copyrights in its carton design, sued the defendants for infringing these rights. The plaintiffs alleged that the defendants were deceptively imitating their product ('Simptran Tablets') using a similar carton and mark since 1993.
Detailed Summary
In the fiercely competitive pharmaceutical industry, a brand's identity is often its most valuable asset. When a competitor doesn't just copy your name but replicates your entire packaging design, the line between competition and deception becomes dangerously thin. This case demonstrates why protecting both trademarks and copyrights together can be a startup's strongest shield against copycats.
Burroughs Wellcome (India) Ltd., the plaintiffs, were the registered owners of the trademark 'Septran' and held copyrights in the artistic design of the carton used for their product. The defendants, Uni-Sole Pvt. Ltd. and another party, allegedly began selling a product called 'Simptran Tablets' in 1993. The plaintiffs claimed that the defendants were not merely offering a competing product but were engaging in deceptive imitation by using a strikingly similar carton design and a confusingly similar mark, effectively riding on the goodwill and reputation built by the plaintiffs over the years.
The plaintiffs argued that the defendants' adoption of the 'Simptran' mark and the similar carton design constituted both trademark infringement and copyright infringement, as well as passing off. They contended that the visual and phonetic similarities were designed to confuse consumers and capitalize on the established reputation of the 'Septran' brand. The defendants, on the other hand, were alleged to have made subsequent alterations to their packaging, attempting to differentiate their product. The core legal friction centered on whether these alterations were sufficient to escape liability, and whether the plaintiffs could successfully seek an injunction to halt the allegedly deceptive practices.
The court ruled in favor of the plaintiffs, issuing an interim order that recognized the strength of their registered copyright and trademark claims. The court reasoned that the plaintiffs had established a prima facie case of infringement and passing off. Importantly, the court held that the defendants' subsequent alterations to the artistic work or packaging did not absolve them of liability. The registered copyright and trademark served as valid grounds for seeking injunctive relief, reinforcing that intellectual property protections remain robust even when infringers attempt to make minor modifications to their copied designs.
For founders and IP professionals, this case delivers a clear lesson: do not rely solely on a trademark registration when your product's visual identity is a key part of its market appeal. Registering copyrights for your packaging designs, carton artwork, and other creative elements creates a layered defense that is much harder for competitors to circumvent. Even if a copycat tweaks their version of your design, your registered rights can still form the basis of a strong injunction. In the battle against deceptive imitation, a dual strategy of trademark and copyright protection is not just advisable—it is essential.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Bombay High Court. Understanding the court's reasoning in Burroughs Wellcome (India) Ltd. vs Uni-Sole Pvt. Ltd. And Another is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
INCYTE HOLDINGS CORPORATIONvsGLENMARK PHARMACEUTICALS LIMITED
The plaintiffs sought a decree of permanent injunction against the defendants concerning Indian Patent No. 269841. The defendants submitted that they had not commercialized any product containing 'Ruxolitinib' and did not intend to do so in the future.
Indena S.P.A.vsController General Pf Patents, Designs and Trademarks and Anr.
This case involves Indena S.P.A. appealing a matter previously handled by the Intellectual Property Appellate Board (IPAB). Following the enactment of the Tribunals Reform Act, 2021, the matter was transferred to the Calcutta High Court's Commercial Division. The court directed that notices be issued to both parties and a report filed before the returnable date, setting the next hearing for March 6, 2023.
The Chinese University of Hong KongvsThe Assistant Controller of Patents and Designs
The Chinese University of Hong Kong appealed an order rejecting its patent application for a method related to detecting genetic aberrations associated with cancer. The appellant argued that the rejections under Sections 3(i), 3(k), and 10(4)(c) were flawed, citing lack of reasoning and procedural unfairness. The High Court set aside the impugned order and remanded the matter for fresh consideration.
Celligence International LlcvsDeputy Controller Of Patents And Designs
Celligence International Llc filed an appeal against an order dated 30.06.2025 issued by the Deputy Controller of Patents and Designs regarding Indian patent application no. 202117058456. The court issued notice to the respondent, directing them to file a reply within four weeks.
AMST – SYSTEMTECHNIK GMBHvsGovernment of India
The petitioner challenged an order treating its Patent Application No.3022/CHENP/2011 as withdrawn due to failure to request examination within the stipulated period. The court considered the sequence of events, noting that the petitioner intended to prosecute the application and citing previous judgments where similar facts led to non-withdrawal.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.